Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities
© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc..
Molecular profiling guides precision treatment of breast cancer; however, Asian patients are underrepresented in publicly available large-scale studies. We established a comprehensive multiomics cohort of 773 Chinese patients with breast cancer and systematically analyzed their genomic, transcriptomic, proteomic, metabolomic, radiomic and digital pathology characteristics. Here we show that compared to breast cancers in white individuals, Asian individuals had more targetable AKT1 mutations. Integrated analysis revealed a higher proportion of HER2-enriched subtype and correspondingly more frequent ERBB2 amplification and higher HER2 protein abundance in the Chinese HR+HER2+ cohort, stressing anti-HER2 therapy for these individuals. Furthermore, comprehensive metabolomic and proteomic analyses revealed ferroptosis as a potential therapeutic target for basal-like tumors. The integration of clinical, transcriptomic, metabolomic, radiomic and pathological features allowed for efficient stratification of patients into groups with varying recurrence risks. Our study provides a public resource and new insights into the biology and ancestry specificity of breast cancer in the Asian population, offering potential for further precision treatment approaches.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Nature cancer - (2024) vom: 12. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jiang, Yi-Zhou [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 12.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1038/s43018-024-00725-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368372766 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368372766 | ||
| 003 | DE-627 | ||
| 005 | 20240213233123.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240213s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s43018-024-00725-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1291.xml |
| 035 | |a (DE-627)NLM368372766 | ||
| 035 | |a (NLM)38347143 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jiang, Yi-Zhou |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer Nature America, Inc. | ||
| 520 | |a Molecular profiling guides precision treatment of breast cancer; however, Asian patients are underrepresented in publicly available large-scale studies. We established a comprehensive multiomics cohort of 773 Chinese patients with breast cancer and systematically analyzed their genomic, transcriptomic, proteomic, metabolomic, radiomic and digital pathology characteristics. Here we show that compared to breast cancers in white individuals, Asian individuals had more targetable AKT1 mutations. Integrated analysis revealed a higher proportion of HER2-enriched subtype and correspondingly more frequent ERBB2 amplification and higher HER2 protein abundance in the Chinese HR+HER2+ cohort, stressing anti-HER2 therapy for these individuals. Furthermore, comprehensive metabolomic and proteomic analyses revealed ferroptosis as a potential therapeutic target for basal-like tumors. The integration of clinical, transcriptomic, metabolomic, radiomic and pathological features allowed for efficient stratification of patients into groups with varying recurrence risks. Our study provides a public resource and new insights into the biology and ancestry specificity of breast cancer in the Asian population, offering potential for further precision treatment approaches | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Ma, Ding |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Xi |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Jinxiu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Yi-Fan |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Tong |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Cai-Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Lei-Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Cheng-Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Shen |e verfasserin |4 aut | |
| 700 | 1 | |a Su, Guan-Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Hou, Wanwan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yaqing |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Qingwang |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jingcheng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Naixin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Wen-Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Ge, Weigang |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Wen-Tao |e verfasserin |4 aut | |
| 700 | 1 | |a You, Chao |e verfasserin |4 aut | |
| 700 | 1 | |a Gu, Yajia |e verfasserin |4 aut | |
| 700 | 1 | |a Kaklamani, Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a Bertucci, François |e verfasserin |4 aut | |
| 700 | 1 | |a Verschraegen, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Daemen, Anneleen |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Nakul M |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Tiannan |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Leming |e verfasserin |4 aut | |
| 700 | 1 | |a Perou, Charles M |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Yuanting |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Shao, Zhi-Ming |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature cancer |d 2020 |g (2024) vom: 12. Feb. |w (DE-627)NLM307030067 |x 2662-1347 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:12 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s43018-024-00725-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 12 |c 02 | ||